SOURCE: PharmaRoth Labs, Inc.

November 02, 2015 08:30 ET

PharmaRoth Labs Announces New Sales Agreement in India

Company Inks Deal With Canagen Pharmaceuticals

LAS VEGAS, NV--(Marketwired - Nov 2, 2015) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that it has signed an exclusive distribution and sales agreement with Canagen Pharmaceuticals for the country of India. The agreement gives Canagen exclusive rights to sell and distribute Sucanon® throughout India for 5 years, and in total represents $85 million over those years in gross sales.

"I am very pleased that we are continuing to expand our geographical reach, especially into a market such as India," commented Luis Lopez, CEO of PharmaRoth. "We are extremely proud to have a partner like Canagen in the largest market, to date, for our Type-II Diabetes treatment."

The company must conduct a limited 12-week clinical trial in Mexico before final approval from the Ministry in India. "We have been working with Dr. Rojas, our Advisor in Mexico, on the protocols and patients for this clinical. His expertise is known globally and we are very excited to have another clinical trial to showcase the strength of Sucanon®."

For more information regarding Canagen Pharmaceuticals, Inc, please visit: http://www.canagen.com/about.php

About Sucanon®

Sucanon® is a diabetes oral treatment containing natural ingredients. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.

For more information regarding Sucanon®, please visit www.pharmaroth.com

About PharmaRoth

PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive worldwide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements

Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.

Contact Information

  • For Investor Relations contact:

    Michael Irving
    Paramount Advisors, LLC
    (407) 878-5462
    mike@parvise.com